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Abstract
Aims: Benzodiazepine receptor agonists (BZ-RAs) are frequently prescribed to treat 
insomnia; however, their long-term use is not recommended. To introduce an appro-
priate pharmaco-therapy, the current state and background factors of BZ-RAs' de-
pendence must be elucidated. In this study, we developed a Japanese version of the 
Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ-J) and con-
ducted a study of BZ-RAs' use disorder.
Methods: The Bendep-SRQ-J was created with permission from the original devel-
oper. Subjects were inpatients and outpatients receiving BZ-RAs between 2012 and 
2013. Clinical data collected were Bendep-SRQ-J scores, sleep disorders for which 
BZ-RAs were prescribed, physical comorbidities, psychotropic drugs, and lifestyle 
factors. Logistic analysis was performed to extract factors associated with severe 
symptoms.
Results: Of the 707 patients prescribed BZ-RAs, 324 had voluntarily tapered or 
discontinued their drugs. Logistic analysis showed that the total number of drugs 
administered in the last 6 months correlated with both worsening of symptoms or 
conditions. This was more notable among younger patients, and the proportion of 
patients with severe symptoms or conditions increased with the increasing number 
of drugs.
Conclusion: Using the Bendep-SRQ-J, we elucidated the current state of BZ-RA de-
pendence. Nearly half of the patients were non-compliant. The proportion of patients 
with severe symptoms or disease conditions increased with the increase in the num-
ber of drugs administered. These findings highlight the need for clinicians to be aware 
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1  | INTRODUC TION
Insomnia is a highly prevalent and serious disorder with far-reaching 
clinical and socioeconomic consequences. The prevalence of insom-
nia varies among studies, depending on the definition used,1 but it has 
been reported to range from 6% to 30%.1–7 Chronic insomnia intensi-
fies anxiety/strain experienced due to the symptoms and causes phys-
iological and emotional arousal and compensatory daytime sleepiness, 
thus compromising daytime quality of life8–12. Consequently, insomnia 
is thought to contribute to workforce and socioeconomic losses by in-
creasing long-term absenteeism and industrial accidents, decreasing 
performance and productivity, and increasing healthcare costs.13–16
Benzodiazepine receptor agonists (BZ-RAs) are frequently used 
for the treatment of insomnia. BZ-RAs provide anxiolytic, sedative, 
and hypnotic effects by acting as agonists of gamma-aminobutyric 
acid (GABA) receptors.17 According to an epidemiological study of the 
frequency of BZ-RA prescriptions, 3.66% of the Japanese population 
(3.02% in men, 4.29% in women) were prescribed hypnotics in 2005.18 
The frequency of BZ-RA prescriptions also increases with age and with 
increasing numbers of physical comorbidities in both men and women. 
In 2002, a Canadian survey found that 2.5% to 4.2% of Canadians were 
taking hypnotics19, the 3-month prescription rate estimated in both the 
Japanese and Canadian studies was comparable.
In the United States, a 1985 survey report showed that 2.6% of 
the population used hypnotics and 4.3% used antidepressants or 
anxiolytics prescribed as alternatives to hypnotics over a 1-year pe-
riod.5 Also, 3.1% of the population used over-the-counter sleep aids.
The known problems and risks of BZ-RAs, which are commonly 
prescribed for the treatment of insomnia, include carry-over effects, 
falls due to lightheadedness,20,21 cognitive decline and amnesia,22,23 
traffic accidents,24–27 and dependence.28–31 Thus, BZ-RAs are not 
recommended for use in middle-aged and elderly patients with 
chronic insomnia, although they are often the major users.17,32,33 
In addition, high-dose BZ-RAs, concurrent use with multiple drugs, 
and long-term use are not recommended because of aggravation of 
BZ-RA side effects. Despite these drawbacks, BZ-RAs have continu-
ously been used on a long-term basis in clinical settings, even though 
they cause dependence in the broad sense.
Since the early 1960s, BZ-RA dependence has been debated. 
Because of anxiety over insomnia symptoms and withdrawal symp-
toms, patients on BZ-RAs continue to use the drugs without having 
intended to do so, sometimes leading to problems related to drug 
use, such as non-compliance with treatment regimens and problem-
atic drug use. Thus, BZ-RA-dependence is regarded as a use disorder.
Against this background, it is anticipated that long-term admin-
istration of hypnotics is a risk factor for substance use disorder. It is 
therefore desirable to introduce an appropriate drug tapering/dis-
continuation program for patients who have been taking hypnotics 
for a prolonged period. To establish an appropriate discontinuation 
program, it is important to elucidate and accurately evaluate the cur-
rent state and background factors of hypnotic use disorder. To date, 
no studies have reported data that accurately describe the incidence 
and severity of hypnotic use disorder in Japan. This is partly due to 
a lack of clinically useful criteria for assessing the severity of this 
disorder in Japanese patients.
Several self-report questionnaires have been developed 
for assessing BZ-RA dependence, including the Composite 
International Diagnostic Interview,34 Schedules for Clinical 
Assessment in Neuropsychiatry,35 and Benzodiazepine Dependence 
Questionnaire36, but all the criteria have some deficits. Consequently, 
the Benzodiazepine Dependence Self-Report Questionnaire 
(Bendep-SRQ)37 was developed as a multidimensional tool for com-
prehensive assessment of BZ-RA dependence.
Studies on Bendep-SRQ have been reported and these studies 
investigated the characteristics of patients with cravings for BZ-
RAs;38 risk factors for BZ-RA dependence;39 cross-validation, pre-
dictive validity, and change in Bendep-SRQ scores over time;40 the 
dependence potential of antidepressants compared with benzodi-
azepines;41 and cross-validation of the Bendep-SRQ.42,43 However, 
these studies were not conducted in Japan, and so Japanese patients 
have not been studied.
In light of the above, we developed the Japanese version of 
Bendep-SRQ (Bendep-SRQ-J) and conducted a multicenter collabora-
tive study to clarify the current state of BZ-RA use disorder in Japan.
2  | METHODS
2.1 | Development of the Bendep-SRQ-J
With permission from the developer of the original Bendep-SRQ, 
we translated the questionnaire into Japanese, back-translated it, 
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and made inquiries about medications, before developing the final 
Japanese version.
The Bendep SRQ37 consists of 20 questions in 4 dimensions: (1) 
preoccupation with drug availability, (2) problematic drug use, (3) 
non-compliance with treatment regimen, and (4) withdrawal symp-
toms. This study also included withdrawal insomnia as a fifth dimen-
sion to evaluate the withdrawal symptoms unique to hypnotics. All 
patients answered 15 questions in dimensions 1-3, and patients who 
had previously tapered drugs also answered questions in dimen-
sions 4 and 5. Each dimension has a cutoff point, and the severity of 
symptoms/conditions is classified into 3-5 grades (Figure S1).
2.2 | Self-administered questionnaire survey
In this multicenter collaborative study, a self-administered cross-sec-
tional survey was conducted with inpatients and outpatients receiving 
drug therapy with BZ-RA hypnotics or anxiolytics at 14 participating 
medical institutions over a period of 3 months, between August 2012 
and March 2013. Additionally, patient information was obtained from 
primary care physicians, including the sleep disorder necessitating the 
prescription of BZ-RAs, physical comorbidities, psychotropic drugs 
prescribed during a period of 180 days (6 months) prior to the survey, 
and lifestyle factors including alcohol consumption.
2.3 | Definition of drugs
BZ-RAs were classified as hypnotics when prescribed to provide 
sedative-hypnotic effects at night or as anxiolytics (BZ-A) when pre-
scribed to provide anxiolytic effects during the day. BZ-RA hypnot-
ics were classified as BZ-hypnotics (BZ-H), which are drugs with a 
benzodiazepine (BZ) backbone in their chemical structure or as non-
BZ-hypnotics (non-BZ-H) for those without a BZ backbone that have 
high selectivity for the α1 subunit (zopiclone, eszopiclone, and zolpi-
dem). The distinction between non-BZ-H and BZ-H was made in this 
study because there is a lower incidence of withdrawal symptoms 
and lower risk of developing dependence with non-BZ-H.44 In addi-
tion, patients were divided by drug category and were analyzed sep-
arately to reveal the differences in actual drug use and risk factors.
2.4 | Statistical analysis
Bendep-SRQ scores and patient background factors were compared 
in order to extract background factors for BZ-RA use disorder. Also, 
to extract factors associated with severe or extremely severe symp-
toms/conditions in each dimension, logistic regression analysis was 
performed using the following as independent variables: sex, age 
(20-44, 45-64, or 65-90 years), presence/absence of mental or phys-
ical disorder, drug category (BZ-H, non-BZ-H, or BZ-A), daily drug 
dose (<10 mg or ≥10 mg of BZ-H, non-BZ-H, or BZ-A), and the total 
number of drugs administered in the last 3 months (1, 2, or ≥3 drugs). 
To reveal the specific features of BZ-H, non-BZ-H, and BZ-A, the 
clinical data of patients receiving each of these monotherapies were 
extracted and analyzed separately in logistic analysis. Statistical 
analysis was conducted using the IBM SPSS Statistics software (Ver. 
22).
2.5 | Ethical considerations
The protocol for this research project has been approved by a suit-
ably constituted Ethics Committee of the institution and it con-
forms to the provisions of the Declaration of Helsinki. Committee of 
National Center of Neurology and Psychiatry, Approval No. A2012-
065. All informed consent was obtained from the subjects.
3  | RESULTS
3.1 | Background characteristics
Surveys were returned by 922 patients treated with BZ-RAs, of 
whom 215 provided invalid data such as unclear or unrealistic re-
sponses. Table 1 shows the background characteristics of the pa-
tients. Of the 707 patients with valid responses, 198, 99, and 115 
(412 in total) were receiving monotherapy with BZ-H, non-BZ-H, or 
BZ-A, respectively.
Table 2 shows drugs belonging to the BZ-H, non-BZ-H, and BZ-A 
categories and the number of patients on each drug. Of the 707 pa-
tients treated with BZ-RAs, 324 (45.8%) had previously tapered/dis-
continued their drug use, and 187 (45.4%) of the 324 patients were 
receiving monotherapy with BZ-H (n = 86), non-BZ-H (n = 49), or 
BZ-A (n = 52).
3.2 | Severity of Bendep-SRQ dimensions and 
withdrawal symptoms and insomnia
Among all patients (N = 707), the Bendep-SRQ dimensions of pre-
occupation with drug availability, medication non-compliance, and 
problematic drug use were severe in 32.4%, 29.0%, and 32.4%, re-
spectively. Among patients who had previously tapered/discontin-
ued their drug use (n = 324), withdrawal symptoms were severe in 
10.8% and withdrawal insomnia was severe in 30.9%.
3.3 | Factors associated with severe/extremely 
severe symptoms/conditions in each dimension
1. All subjects (N = 707, Table 3).
Age < 44 years had a significant correlation with severe 
or extremely severe non-compliance with treatment regimen, 
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problematic drug use, withdrawal symptoms, and withdrawal insom-
nia. Presence of physical disorder had a significant correlation with 
severe or extremely severe non-compliance with treatment regimen. 
Additionally, there was a significant correlation between use of ≥3 
drugs and severe or extremely severe symptoms/conditions in all di-
mensions. Use of 2 drugs also correlated with severe or extremely 
severe preoccupation with drug availability, problematic drug use, 
and withdrawal symptoms. Total dose of BZ-RAs administered in the 
last 3 months was not associated with severe or extremely severe 
symptoms/conditions in any of the dimensions.
1. Patients receiving monotherapy with BZ-A (n = 115, Table 4).
Presence of physical disorder had a significant correlation with 
severe or extremely severe non-compliance with treatment reg-
imen. Total dose of BZ-RAs in the last 3 months was not associ-
ated with severe or extremely severe symptoms/conditions in any 
of the dimensions. No withdrawal symptoms are listed because 
there were no cases of severe dependence. The distributions of 
severalty among the 52 participants were very mild 42, mild 5, 











707 198 99 115
Age, y
Mean age (SD) 53.2 (16.5) 52.9 (17.0) 52.9 (18.8) 53.1 (15.4)
Range 20-90 20-87 21-88 22-86
Sex, n (%)
Men (%) 322 (45.5) 90 (45.5) 50 (50.5) 53 (46.1)
Women (%) 385 (54.5) 108 (54.5) 49 (49.5) 62 (53.9)
Number of drugs, n
Mean 2 1.4 1.1 1.2
Dose of Bz-RAs, mg
Mean 9.6 6.5 4.2 6.5
Comorbidity, n (%)
Mental disorder 460 (65.1) 136 (68.7) 43 (43.4) 76 (66.1)
Physical 
disorder
261 (36.9) 57 (28.8) 47 (47.5) 49 (42.6)
Patients with a history of drug tapering
Number of patients, n
Number (% to 
total)
324 (45.8) 86 (43.4) 49 (49.5) 52 (45.2)
Age, y
Mean age (SD) 53.3 (16.5) 50.62 (17.1) 54.84 (17.0) 54 (16.4)
Range 20 to 90 21 to 84 22 to 85 20 to 90
Sex, n (%)
Men (%) 156 (48.1) 45 (52.3) 25 (51.0) 22 (42.3)
Women (%) 168 (51.9) 41 (47.7) 24 (49.0) 30 (57.7)
Number of drugs, n
Mean 2 1.4 1.1 1.3
Dose of Bz-RAs, mg
Mean 9.3 8.2 4.2 7
Comorbidity, n (%)
Mental disorder 205 (63.3) 54 (62.8) 22 (44.9) 33 (63.5)
Physical 
disorder
125 (38.6) 27 (31.4) 25 (51.0) 24 (46.2)
Abbreviation: BZ-A, benzodiazepine agonistic anxiolytics; Bz-H, benzodiazepine agonistic 
hypnotics; Non-BZ-H, benzodiazepine agonistic hypnotics without benzodiazepine chemical 
structure.
TA B L E  1   Patient background 
information
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1. Patients receiving monotherapy with BZ-H (n = 198, Table 5).
Age < 44 years had a significant correlation with severe or ex-
tremely severe non-compliance with treatment regimen, problem-
atic drug use, and withdrawal insomnia. Use of ≥3 drugs correlated 
significantly with severe or extremely severe preoccupation with 
drug availability, while use of 2 drugs had a significant correlation 
with severe or extremely severe withdrawal insomnia. Total dose of 
BZ-RAs in the last 3 months was not associated with severe or ex-
tremely severe symptoms/conditions in any of the dimensions.
1. Patients receiving monotherapy with non-BZ-H (n = 99, Table 6).
Age < 44 years correlated significantly with severe or extremely 
severe problematic drug use. Presence of physical disorder cor-
related significantly with severe or extremely severe preoccupation 
with drug availability. Additionally, use of 2 drugs had a significant 
correlation with severe or extremely severe preoccupation with 
drug availability, non-compliance with treatment regimen, and prob-
lematic drug use. Total dose of BZ-RAs in the last 3 months was not 
associated with severe or extremely severe symptoms/conditions in 
any of the dimensions.
Incidence of withdrawal insomnia based on the number of drugs 
administered.
The investigation of withdrawal insomnia appearing in 324 pa-
tients who had previously tapered/discontinued their drug use re-
vealed that an incidence of 20.5% in patients taking 1 drug, 27.20% 
in those taking 2 drugs, and 54.40% in those taking ≥3 drugs, 
indicating that the proportion of patients with severe or extremely 
severe withdrawal insomnia increased with the increasing number 
of drugs. Compared with those receiving monotherapy with BZ-H, 
non-BZ-H, or BZ-A, patients taking 2 drugs had a higher incidence of 
severe or extremely severe withdrawal insomnia. However, no sta-
tistical analysis was performed on patients taking ≥3 drugs due to 
the small sample size.
4  | DISCUSSION
In this study, using the Bendep-SRQ-J, a rating scale for BZ-RA de-
pendence, we investigated the current state of BZ-RA dependence 
among patients treated at sleep disorder outpatient clinics in Japan. 
The results showed that approximately 30% of patients had a se-
vere or extremely severe preoccupation with drug availability, non-
compliance with treatment regimen, and problematic drug use. Of 
all patients receiving drug therapy with BZ-RAs, 45% had previously 
tapered/discontinued their drug use. The frequency of withdrawal 
symptoms by the number of drugs administered in this patient pop-
ulation was approximately 20% in patients taking 1 drug and 40% 
in those taking multiple drugs. Approximately 10% and 30% of the 
patients had severe or extremely severe withdrawal symptoms and 
withdrawal insomnia, respectively.
This study revealed a high incidence of voluntary drug discon-
tinuation. A previous survey of international comparisons of aware-
ness of hypnotics has shown that Japanese people have particularly 
high levels of anxiety and psychological resistance toward hypnotics, 
Bz-RAs-H (n = 198) Non-Bz-RAs-H (n = 99) Bz-RAs-A (n = 115)
Brotizolam 149 (48) Eszopiclone 18 (1) Alprazolam 54 
(23)
Clonazepam 22 (4) Zolpidem 158 (58) Bromazepam 34 (9)
Cloxazolam 1 (-) Zopiclone 63 (23) Chlordiazepoxide 4 (-)
Diazepam 1 (-) Clonazepam 44 (13)
Estazolam 15 (2) Clotiazepam 14 (6)
Etizolam 36 (11) Cloxazolam 7 (2)
Flunitrazepam 139 (27) Diazepam 22 (3)
Flurazepam 1 (-) Etizolam 60 (28)
Haloxazolam 1 (-) Loflazepate 36 (7)
Loflazepate 5 (-) Lorazepam 45 (8)
Lormetazepam 10 (2) Lormetazepam 1 (-)
Nimetazepam 1 (-) Medazepam 1 (-)




Note: (), number of patients receiving monotherapy with this drug.
Abbreviations: BZ-A, benzodiazepine agonistic anxiolytics; Bz-H, benzodiazepine agonistic 
hypnotics; Non-BZ-H, benzodiazepine agonistic hypnotics without benzodiazepine chemical 
structure.
TA B L E  2   Drugs in the Bz-RAs-H, non-
Bz-RAs-H, and Bz-RAs-A categories and 
the number of patients on each drug
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which apparently contribute as background factors to the high inci-
dence of voluntary drug discontinuation among Japanese individuals.
Compared with older age groups, patients aged 20-44 years 
(younger patients) had more severe or extremely severe use prob-
lems, such as non-compliance with treatment regimen and problem-
atic drug use. The findings of this cross-sectional study do not reveal 
any causal relationship among the severe symptoms/conditions, 
but previous studies have pointed out that physical dependence 
(formation of tolerance) is a risk factor for BZ-RA dependence. For 
example, according to studies using clinical data suggesting toler-
ance to BZ-RAs, the prescribed dose of BZ-RAs did not increase over 
time generally, but gradually did so among younger patients.45,46 
However, because no correlation was observed between depen-
dence symptoms and BZ-RA dose in the present study, it is diffi-
cult to think that waning of efficacy due to development of drug 
tolerance is a direct cause of drug use disorder. Although there are 
not certain data about the rate of comorbidity, the group of patients 
aged 20-44 years tended to have some form of comorbid mental 
health issue, such as anxiety. We speculate that they may be anxious 
due to recurring anxiety or insomnia and that this may contribute to 
psychological dependence on hypnotics.
As for patients taking BZ-A, younger age was not associated with 
severe or extremely severe symptoms/conditions in any of the di-
mensions. However, this does not necessary mean that the risk of 
dependence is lower with BZ-A than with BZ-H or non-BZ-H. A fail-
ure to reveal risk factors for BZ-RA anxiolytics among patients taking 
BZ-A in this study could suggest that compared with the severity of 
insomnia, the severity of mental disorders such as anxiety disorder 
and somatic symptom disorder, both of which are the target of BZ-A, 
was milder because these patients were treated at clinics specialized 
in sleep disorders. Indeed, most patients were on the recommended 
dose of BZ-A (a table will be developed to show the data), and it is 
likely that only a small number of patients had severe symptoms, 
were taking higher doses, or were taking it for an extended period.
4.1 | Relationship between dose and Bendep-
SRQ-J score
Previous studies have shown that the risk factors for BZ-RA depend-
ence include long-term use,47,48 high dose,48,49 comorbidity with 
mental disorder48, severe insomnia49, and alcohol dependence.49 
However, despite our expectations, no correlation was observed 
between BZ-RA dose and severity of benzodiazepine dependence 
[[Bendep-SRQ-J scores]] in this study.
This suggests that the Bendep-SRQ-J might not accurately as-
sess withdrawal symptoms because it is a self-administered ques-
tionnaire. For example, anxiety, frustration, and insomnia are the 
major symptoms of BZ-RA withdrawal,50 but they are also symptoms 
already present in patients with insomnia (the disorder requiring 
BZ-RAs). Another possible reason why no correlation was found be-
tween dose and withdrawal symptoms was that the subjects in this 
study did not take multidrug combinations of BZ-H, non-BZ-H, and 
BZ-A. Multidrug combination is a risk factor for drug use disorder, 
but in this study, multidrug cases across drug classes were excluded.
4.2 | Relationship between number of drugs 
administered and Bendep-SRQ-J score
In this study, a correlation was observed between the number of 
drugs administered during the last 6 months and high Bendep-
SRQ-J scores. Patients taking multiple drugs had a strong tendency 
toward drug use disorder and dependence, compliance issues, 
and a high rate of withdrawal symptoms. As is clear from the data 
showing the lack of correlation with drug dose, multiple drug use 
was mainly attributable to drug switching in the short term. In this 
study, we did not cover the reasons for drug switching, and there-
fore the background factors remain unclear. However, it is possible 
that anxiety and insomnia, both of which are the target disorders of 
BZ-RAs, were intractable. Moreover, patients might have requested 
more effective drugs due to severe anxiety over their symptoms. 
In such cases, it is easy to imagine that patients are strongly de-
pendent on their drugs, likely leading to non-compliance with the 
treatment regimen or problematic drug use. Third, physicians might 
have switched drugs at a faster pace than necessary in response to 
the patient's request. Drug prescriptions lacking clinical evidence 
may become a remote cause of high-dose prescriptions or multiple 
prescriptions, in addition to interfering with the improvement of 
treatment efficacy.
4.3 | Limitations
Because this was a cross-sectional study, we were unable to inves-
tigate changes over time. Additionally, patients on multiple drugs 
across different drug categories were not included in the analysis. 
Although patients on multiple drugs are regarded as a problem in ac-
tual clinical practice, these patients were excluded in this study, and 
so these results should be applied with caution in clinical settings.
5  | CONCLUSION
Using the Bendep-SRQ-J, we elucidated the current state of BZ-RA 
use disorder in this study. Approximately 45% of the patients re-
ceiving drug therapy with BZ-RAs had voluntarily tapered/discon-
tinued their drug use in the past, revealing problems associated 
with non-compliance with the treatment regimen. Additionally, the 
number of drugs administered during the last 6 months significantly 
contributed to worsening of the preoccupation with drug avail-
ability, drug use disorder (non-compliance with treatment regimen 
and problematic drug use), withdrawal symptoms, and withdrawal 
insomnia. These findings were notable among younger patients, 
and the proportion of patients with severe symptoms/conditions 
increased with an increase in the number of drugs administered. 
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In contrast, no correlation was observed between BZ-RA dose and 
dimensions of the Bendep-SRQ-J. The findings highlight the need 
for clinicians to be aware of the likelihood of benzodiazepine de-
pendence, specifically in young patients and patients prescribed 
multiple hypnotics.
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